ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
칼시뉴린 억제제 시장 규모는 향후 수 년간 강력한 성장이 예상될 예정입니다. 예측 기간 동안의 성장은 칼시뉴린 억제제 시장 확대, 자가면역질환 유병률 증가, 만성 신장 질환 사례 증가로 인한 이식 증가, 아토피 피부염 및 건선 발생률 증가 등의 요인에 기인할 수 있습니다. 이 기간의 주요 동향으로서는 효능 향상을 위한 약제 제제의 진보, 서방형 제제의 개발, 칼시뉴린 억제제와의 병용 요법의 연구, 드러그 전달 방법의 혁신, T세포 시그널 경로에 대한 더 나은 이해 등이 있습니다.
장기 이식 증가는 칼시뉴린 억제제 시장의 확대를 촉진할 것으로 예측됩니다. 압력과 같은 만성 질환의 유병률이 증가함에 따라 이들은 종종 장기 부전으로 이어지고 이식 수요를 증가시키고 있습니다. 거부반응의 위험을 줄임으로써 장기이식에 중요한 역할을 하고 있습니다. 2025년 1월에 미국에 기반을 둔 이식 정보 데이터베이스인 장기 조달 및 이식 네트워크(OPTN)는 2024년 장기 이식 건수가 4만 8,000건을 넘어 2023년 대비 3.3% 증가했다고 보고했습니다.
칼시뉴린 억제제 시장의 주요 기업은 과도한 면역 반응을 조절하고, 염증을 억제하고, 조직 손상을 예방하는 것을 목적으로 하는 자가면역 질환의 치료를 포함한 면역억제 요법의 개발에 주력하고 있습니다. 약물, 질병 변형성 항류마티스 약물(DMARDs) 등을 포함한 이러한 치료법은 과도한 면역 반응을 억제하여 면역계를 조절하는 데 도움이 됩니다. 2024년 4월, 인도에 본사를 둔 바이오 제약 회사인 바이오콘 리미티드는 이식 환자의 장기 거부 반응을 예방하는 데 사용되는 칼시뉴린 억제제이며 면역 억제제인 타크로리무스에 대해 남아프리카 보건 제품 규제청(SAHPRA)으로부터 승인을 취득했습니다. 타크로리무스는 면역필린 FKBP-12와 결합하여 복합체를 형성하고 칼시뉴린의 활성을 저해함으로써 이식장기에 대한 면역반응에 중요한 인터루킨 2(IL-2)의 생산과 T세포의 증식을 억제합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 칼시뉴린 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 칼시뉴린 억제제 시장 : 성장률 분석
세계의 칼시뉴린 억제제 시장 실적 : 규모와 성장, 2019-2024
세계의 칼시뉴린 억제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 칼시뉴린 억제제 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 칼시뉴린 억제제 시장 : 제품별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
브랜드
제네릭
세계의 칼시뉴린 억제제 시장 : 투여량별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
정제 및 캡슐
연고
주사
기타 용량
세계의 칼시뉴린 억제제 시장 : 적응증별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
장기 이식
자가면역질환
기타 적응증
세계의 칼시뉴린 억제제 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
재택 케어 환경
약국
세계의 칼시뉴린 억제제 시장 : 브랜드별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
특허의약품
독자적인 처방
세계의 칼시뉴린 억제제 시장 : 제네릭별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
특허 끊어진 동등물
바이오시밀러
제7장 지역별/국가별 분석
세계의 칼시뉴린 억제제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 칼시뉴린 억제제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
칼시뉴린 억제제 시장 : 경쟁 구도
칼시뉴린 억제제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Viatris Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Astellas Pharma Inc.
Bausch Health Companies Inc.
Huadong Medicine Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Cipla Ltd.
Lupin Pharmaceutical Inc.
Zydus Cadila
Biocon Limited
Glenmark Pharmaceuticals Ltd.
Accord Healthcare Ltd.
Strides Pharma Science Limited
Harrow Inc.
Panacea Biotec Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
칼시뉴린 억제제 시장 2029 : 새로운 기회를 제공하는 국가
칼시뉴린 억제제 시장 2029 : 새로운 기회를 제공하는 부문
칼시뉴린 억제제 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Calcineurin inhibitors (CNIs) are a class of immunosuppressant drugs that function by inhibiting calcineurin, a key enzyme involved in T-cell activation, thereby reducing immune responses. These drugs are primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as psoriasis and atopic dermatitis. The most commonly used CNIs are cyclosporine and tacrolimus, both of which block the production of interleukin-2 (IL-2), a vital cytokine for T-cell proliferation.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main forms of calcineurin inhibitors are branded and generic versions. Branded calcineurin inhibitors are patented immunosuppressant drugs marketed under specific trade names by pharmaceutical companies. These are available in various dosages, including tablets, capsules, ointments, injections, and other forms. They are used for organ transplantation, autoimmune diseases, and other conditions. The primary end users of these drugs include hospitals, homecare settings, and pharmacies.
The calcineurin inhibitors market research report is one of a series of new reports from The Business Research Company that provides calcineurin inhibitors market statistics, including calcineurin inhibitors industry global market size, regional shares, competitors with a calcineurin inhibitors market share, detailed calcineurin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcineurin inhibitors industry. This calcineurin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The calcineurin inhibitors market size has grown strongly in recent years. It will grow from$8.84 billion in 2024 to $9.58 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to factors such as faster regulatory approvals for immunosuppressants, favorable reimbursement policies for transplant medications, increasing government support for organ transplantation, the expansion of healthcare infrastructure, and the growth of specialty pharmacies distributing immunosuppressants.
The calcineurin inhibitors market size is expected to see strong growth in the next few years. It will grow to$13.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be attributed to factors such as the expanding calcineurin inhibitors market, the rising prevalence of autoimmune diseases, an increase in chronic kidney disease cases leading to more transplants, a higher incidence of atopic dermatitis and psoriasis, and a growing patient pool for immunosuppressive therapies. Key trends during this period include advancements in drug formulations for improved efficacy, the development of extended-release formulations, research into combination therapies with calcineurin inhibitors, innovations in drug delivery methods, and a better understanding of T-cell signaling pathways.
The growing number of organ transplants is expected to drive the expansion of the calcineurin inhibitors market. Organ transplants involve the surgical replacement of a damaged or failing organ with a healthy one from a donor. The incidence of organ transplants is rising due to the increasing prevalence of chronic diseases such as diabetes and hypertension, which often lead to organ failure and heighten the demand for transplants. Calcineurin inhibitors play a crucial role in organ transplantation by inhibiting T-cell activation, preventing the immune system from recognizing the transplanted organ as foreign, and reducing the risk of rejection. This enhances the long-term survival of the graft. For example, in January 2025, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based transplant information database, reported that organ transplants exceeded 48,000 in 2024, reflecting a 3.3% increase compared to 2023. Therefore, the rise in organ transplant procedures is fueling the growth of the calcineurin inhibitors market.
Key players in the calcineurin inhibitors market are concentrating on the development of immunosuppressive therapies, including treatments for autoimmune diseases, aimed at controlling excessive immune responses, reducing inflammation, and preventing tissue damage. These therapies, which include corticosteroids, immunosuppressants, biologics, and disease-modifying antirheumatic drugs (DMARDs), help regulate the immune system by suppressing overactive immune responses. For example, in April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the South African Health Products Regulatory Authority (SAHPRA) for Tacrolimus, a calcineurin inhibitor and immunosuppressant used to prevent organ rejection in transplant patients. Tacrolimus has been effective in renal transplants for over two decades. It works by binding to the immunophilin FKBP-12, forming a complex that inhibits calcineurin activity, reducing the production of interleukin-2 (IL-2) and T-cell proliferation, which are crucial in the immune response against transplanted organs.
In July 2023, Harrow Inc., a U.S.-based eyecare pharmaceutical company, acquired Santen's branded ophthalmic portfolio for an undisclosed amount. The acquisition provided Harrow with commercial rights to six branded products from Santen, including VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor used to treat vernal keratoconjunctivitis (VKC) in both children and adults, with orphan-drug exclusivity. This acquisition strengthens Harrow's position in the U.S. ophthalmic pharmaceutical market and supports its strategy to become a leading industry player while significantly expanding its branded product offerings. Santen Pharmaceutical Co. Ltd., based in Japan, is a key manufacturer of calcineurin inhibitors.
Major players in the calcineurin inhibitors market are Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Viatris Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Pharmaceutical Inc., Zydus Cadila, Biocon Limited, Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Strides Pharma Science Limited, Harrow Inc., and Panacea Biotec Ltd.
North America was the largest region in the calcineurin inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcineurin inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the calcineurin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The calcineurin inhibitors market consists of sales of topical formulations and diagnostic and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Calcineurin Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on calcineurin inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for calcineurin inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcineurin inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Branded; Generic
2) By Dosage: Tablets And Capsules; Ointments; Injections; Other Dosages
3) By Indication: Organ Transplantation; Autoimmune Disease; Other Indications
4) By End User: Hospitals; Homecare Settings; Pharmacies
Subsegments:
1) By Branded: Patented Drugs; Proprietary Formulations
2) By Generic: Off-Patent Equivalents; Biosimilars
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Calcineurin Inhibitors Market Characteristics
3. Calcineurin Inhibitors Market Trends And Strategies
4. Calcineurin Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Calcineurin Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global Calcineurin Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Calcineurin Inhibitors Market Growth Rate Analysis
5.4. Global Calcineurin Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Calcineurin Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Calcineurin Inhibitors Total Addressable Market (TAM)
6. Calcineurin Inhibitors Market Segmentation
6.1. Global Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded
Generic
6.2. Global Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets And Capsules
Ointments
Injections
Other Dosages
6.3. Global Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Organ Transplantation
Autoimmune Disease
Other Indications
6.4. Global Calcineurin Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare Settings
Pharmacies
6.5. Global Calcineurin Inhibitors Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Patented Drugs
Proprietary Formulations
6.6. Global Calcineurin Inhibitors Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Off-Patent Equivalents
Biosimilars
7. Calcineurin Inhibitors Market Regional And Country Analysis
7.1. Global Calcineurin Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Calcineurin Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
